The novel anti-CD19 autologous CAR T-cell therapy obecabtagene autoleucel achieved durable remissions in 40% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia without a subsequent stem cell transplant, according to results from the phase Ib/II FELIX clinical trial presented by Elias Jabbour, professor of leukemia at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.
When combined with azacitidine, a 7-day course of venetoclax demonstrated similar remission rates and was more tolerable compared to the standard 28-day course for older or chemotherapy-ineligible patients with newly diagnosed acute myeloid leukemia. Results from the retrospective multi-center analysis were presented by Alexandre Bazinet, assistant professor of leukemia at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.
Preliminary data from a phase I study evaluating the novel antibody-drug conjugate M9140 demonstrated encouraging activity in heavily pretreated patients with advanced colorectal cancer. The study was presented by principal investigator Scott Kopetz, professor of gastrointestinal medical oncology and associate vice president for Translational Integration at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.
Preliminary data from the first-in-human phase I trial of RO7623066—a first-in-class inhibitor of ubiquitin-specific peptidase 1—show a promising safety profile as a single agent and signs of early anti-tumor activity for patients with advanced solid tumors. The data were presented by Timothy Yap, professor of investigational cancer therapeutics and vice president and head of clinical development in MD Anderson’s Therapeutics Discovery division, at the 2024 American Society of Clinical Oncology Annual Meeting.
Purple Biotech Ltd. announced positive interim data from its randomized, controlled, open label, multicenter phase II study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma presented at a late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting.
Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have established the most comprehensive molecular portrait of the workings of KRAS and how its activities impact pancreatic cancer outcomes.
The American Cancer Society has published a first-of-its-kind study, “Cancer in People who Identify as Lesbian, Gay, Bisexual, Transgender, Queer or Gender-nonconforming (LGBTQ+)”.
The IQVIA Institute for Human Data Science has released its annual trends report, Global Oncology Trends 2024: Outlook to 2028.
New research out of VCU Massey Comprehensive Cancer Center—published this month in Drug Resistance Updates—revealed a previously unknown biological process through which breast tumor cells develop resistance to standard treatment. It could open the door for cancer scientists to further target this vulnerability and create more effective therapies for disease.
Up to 80% of breast cancer deaths occur in patients with tumors that express estrogen receptor-alpha, according to a study published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
